Table 1.
Ongoing clinical trials exploring combination treatment with targeted therapy and immunotherapy in advanced BRAF-mutant melanoma
| KEYNOTE-022 (13) | IMspire 150 (16) | COMBI-I (15) | |
|---|---|---|---|
| Subjects enrolled | 120 | 514 | 532 |
|
PFS (months) Triplet vs. target |
16.9 vs. 10.7 | 15.1 vs. 10.6 (HR 0.78) | 16.2 vs. 12.0 |
|
ORR (%) Triplet vs. target |
63.3 vs. 71.7 | 66.3 vs. 65.0 | 68.5 vs. 64.2 |
|
DOR (months) Triplet vs. target |
25.1 vs. 12.1 | 21.0 vs. 12.6 | NR vs. 20.7 |
|
OS at 24 months (%) Triplet vs. target |
63 vs. 52 | 60.4 vs. 53.1 | 68 vs. 62 |
|
High grades toxicities (%) Triplet vs. target |
58.3 vs. 25 | 79 vs. 73 | 54.7 vs. 33.3 |